01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2024.
Net product sales were $583.8 milliona for the second quarter of 2024 versus $446.3 million a year earlier, driven by INGREZZA net product sales of $579.5 million. Total revenues were $590.2 million and net income was $65.0 million, or $0.63 per diluted share, compared with $95.5 million, or $0.95 per diluted share, in the second quarter of 2023. For the first six months of 2024, net income was $108.4 million, versus $18.9 million a year earlier, which included $143.9 million of acquired in-process R&D expense tied to the Voyager expansion.
The six-month 2024 results also reflected $138.4 millionb of charges associated with conversions of the 2024 convertible senior notes upon their May 2024 maturity, which were settled in cash for $308.8 million. Research and development expense rose to $191.1 million in the second quarter from $145.8 million, and SG&A rose to $242.0 million from $221.8 million, reflecting commercial investment, pre-launch crinecerfont activities, and a $14.0 million impairment charge on vacated leased office space. Cash and cash equivalents were $139.7 million and total cash, cash equivalents and marketable securities were $1,676.7 million at June 30, 2024.
Stockholders' equity increased to $2,509.2 millionc from $2,232.0 million at year-end 2023, and the company stated its existing resources are sufficient for at least the next 12 months. The filing also discloses a planned CEO transition, with Kevin Gorman retiring on October 11, 2024 and Kyle Gano succeeding him, and FDA acceptance of NDAs with Priority Review for crinecerfont for classic congenital adrenal hyperplasia, with PDUFA target dates of December 29, 2024 and December 30, 2024. Management notes that INGREZZA's qualification as a specified small manufacturer under the Medicare Part D discount program may phase in discounts, and that the overall impact on INGREZZA revenues is inherently uncertain.
02—Key points
Key Highlights
- Net product sales of $583.8 million in Q2 2024, up from $446.3 million in Q2 2023, with INGREZZA contributing $579.5 million.
- Net income of $65.0 million ($0.63 diluted EPS) in Q2 2024, down from $95.5 million ($0.95 diluted EPS) in Q2 2023.
- Six-month 2024 net income of $108.4 million, compared with $18.9 million in the first six months of 2023, which included $143.9 million of acquired IPR&D expense.
- $138.4 million of charges associated with convertible senior notes in the first six months of 2024, tied to the settlement of the 2024 Notes for $308.8 million in cash at maturity on May 15, 2024.
- Total cash, cash equivalents and marketable securities of $1,676.7 million at June 30, 2024; stockholders' equity of $2,509.2 million.
- FDA accepted NDAs with Priority Review for crinecerfont in classic CAH, with PDUFA target dates of December 29, 2024 (capsule) and December 30, 2024 (oral solution).
- Announced CEO transition: Kevin Gorman to retire October 11, 2024, with Kyle Gano succeeding him and joining the Board.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Neurocrine Biosciences kept $0.11.
- Revenue$590.2M100.0%
- Cost of revenue−$9.2M1.6%
- Gross profit$581.0M98.4%
- Operating costs−$435.6M73.8%
- Operating income$145.4M24.6%
- Interest, other & tax−$80.4M13.6%
- Net income$65.0M11.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $590.20M$452.70M | +30.4% |
| Cost of Revenue | $9.20M$11.50M | −20.0% |
| Gross Profit | $581.00M$441.20M | +31.7% |
| SG&A Expenses | $242.00M$221.80M | +9.1% |
| Operating Expenses | $444.80M$379.10M | +17.3% |
| Operating Income | $145.40M$73.60M | +97.6% |
| Net Income | $65.00M$95.50M | −31.9% |
| EPS (Basic) | $0.64$0.98 | −34.7% |
| EPS (Diluted) | $0.63$0.95 | −33.7% |
| Shares Outstanding (Basic) | 100.80M97.60M | +3.3% |
| Shares Outstanding (Diluted) | 103.90M100.20M | +3.7% |
05—Questions
Frequently Asked Questions
What drove revenue growth in the second quarter of 2024?
Net product sales rose to $583.8 million from $446.3 million, primarily reflecting INGREZZA net product sales of $579.5 million, up from $439.7 million. The filing cites strong underlying patient demand and improved gross-to-net dynamics for the six-month increase.
Why did net income decline in the second quarter despite higher revenue?
Operating expenses increased, with R&D rising to $191.1 million from $145.8 million and SG&A to $242.0 million from $221.8 million. Other expense also swung to $(46.8) million, including a $(49.7) million charge tied to convertible senior notes and a $(19.9) million unrealized loss on equity securities, compared with a $37.3 million gain a year earlier.
How did the convertible senior notes affect the company?
The 2024 Notes matured on May 15, 2024 and were settled in full in cash. Holders converted $169.8 million in principal for $308.2 million in cash during the second quarter, and the company recorded $138.4 million of charges for the six months, including a $126.6 million accretion of debt discount and a $9.6 million change in fair value of the derivative liability.
What is the company's liquidity position?
Cash and cash equivalents were $139.7 million at June 30, 2024, and total cash, cash equivalents and marketable securities were $1,676.7 million. Working capital was $1,271.3 million. Management believes existing resources, anticipated INGREZZA sales and investment income will be sufficient for at least the next 12 months.
What leadership and pipeline events were disclosed?
Kevin Gorman, Ph.D. will retire as CEO on October 11, 2024, and Kyle Gano, Ph.D. will succeed him and join the Board. The filing also reports positive topline data from the Phase 2 SAVITRI study of NBI-1065845 in major depressive disorder and the start of a Phase 2 study of NBI-1070770 in MDD.
06—Continue